The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

被引:15
|
作者
Rosende-Roca, Maitee [1 ,2 ]
Abdelnour, Carla [1 ,2 ,3 ]
Esteban, Ester [1 ,2 ]
Tartari, Juan Pablo [1 ,2 ]
Alarcon, Emilio [1 ,2 ]
Martinez-Atienza, Juliana [1 ,2 ]
Gonzalez-Perez, Antonio [1 ,2 ]
Saez, Maria E. [1 ,2 ]
Lafuente, Asuncion [1 ,2 ]
Buendia, Mar [1 ,2 ]
Pancho, Ana [1 ,2 ]
Aguilera, Nuria [1 ,2 ]
Ibarria, Marta [1 ,2 ]
Diego, Susana [1 ,2 ]
Jofresa, Sara [1 ,2 ]
Hernandez, Isabel [1 ,2 ,3 ]
Lopez, Rogelio [1 ,2 ]
Gurruchaga, Miren Jone [1 ,2 ]
Tarraga, Lluis [1 ,2 ,3 ]
Valero, Sergi [1 ,2 ,3 ]
Ruiz, Agustin [1 ,2 ,3 ]
Marquie, Marta [1 ,2 ,3 ]
Boada, Merce [1 ,2 ,3 ]
机构
[1] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Res Ctr, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[2] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Memory Clin, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[3] Inst Salud Carlos III, Networking Res Ctr Neurodegenerat Dis CIBERNED, Madrid, Spain
关键词
Alzheimer's disease; Dementia; Mild cognitive impairment; Sex; Gender; Women; Aging; Education; Elderly; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; DEMENTIA; OLDER; RISK; RECOMMENDATIONS; EPIDEMIOLOGY;
D O I
10.1186/s13195-021-00833-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. Methods This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundacio ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. Results Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). Conclusions The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women's health.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice Position paper of the Dementia and Cognitive Disorders Panel of the European Academy of Neurology
    Ferretti, M. T.
    Martinkova, J.
    Biskup, E.
    Benke, T.
    Gialdini, G.
    Nedelska, Z.
    Rauen, K.
    Mantua, V.
    Religa, D.
    Hort, J.
    Chadha, A.
    Schmidt, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (06) : 928 - 943
  • [22] Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks
    Rahman, Aneela
    Jackson, Hande
    Hristov, Hollie
    Isaacson, Richard S.
    Saif, Nabeel
    Shetty, Teena
    Etingin, Orli
    Henchcliffe, Claire
    Brinton, Roberta Diaz
    Mosconi, Lisa
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [23] Sex and Gender: Critical Variables in Pre-Clinical and Clinical Medical Research
    Morselli, Eugenia
    Frank, Aaron P.
    Santos, Roberta S.
    Fatima, Luciana A.
    Palmer, Biff F.
    Clegg, Deborah J.
    CELL METABOLISM, 2016, 24 (02) : 203 - 209
  • [24] The importance of negative predictive value (NPV) of vulnerable elderly survey (VES 13) as a pre-screening test in older patients with cancer
    B. Castagneto
    C. Di Pietrantonj
    I. Stevani
    A. Anfossi
    M. Arzese
    L. Giorcelli
    L. Giaretto
    Medical Oncology, 2013, 30
  • [25] The importance of negative predictive value (NPV) of vulnerable elderly survey (VES 13) as a pre-screening test in older patients with cancer
    Castagneto, B.
    Di Pietrantonj, C.
    Stevani, I.
    Anfossi, A.
    Arzese, M.
    Giorcelli, L.
    Giaretto, L.
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [26] The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment?
    Evans, Stephanie
    McRae-McKee, Kevin
    Wong, Mei Mei
    Hadjichrysanthou, Christoforos
    De Wolf, Frank
    Anderson, Roy
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2018, 33 (07) : 635 - 644
  • [27] Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application
    Echle, A.
    Laleh, N. Ghaffari
    Quirke, P.
    Grabsch, H., I
    Muti, H. S.
    Saldanha, O. L.
    Brockmoeller, S. F.
    van den Brandt, P. A.
    Hutchins, G. G. A.
    Richman, S. D.
    Horisberger, K.
    Galata, C.
    Ebert, M. P.
    Eckardt, M.
    Boutros, M.
    Horst, D.
    Reissfelder, C.
    Alwers, E.
    Brinker, T. J.
    Langer, R.
    Jenniskens, J. C. A.
    Offermans, K.
    Mueller, W.
    Gray, R.
    Gruber, S. B.
    Greenson, J. K.
    Rennert, G.
    Bonner, J. D.
    Schmolze, D.
    Chang-Claude, J.
    Brenner, H.
    Trautwein, C.
    Boor, P.
    Jaeger, D.
    Gaisa, N. T.
    Hoffmeister, M.
    West, N. P.
    Kather, J. N.
    ESMO OPEN, 2022, 7 (02)
  • [28] A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease
    Geldmacher, David S.
    Fritsch, Thomas
    McClendon, McKee J.
    Landreth, Gary
    ARCHIVES OF NEUROLOGY, 2011, 68 (01) : 45 - 50
  • [29] Clinical Characteristics of Taiwanese Children With Congenital Adrenal Hyperplasia Caused by 21-Hydroxylase Deficiency in the Pre-screening Era
    Lee, Cheng-Ting
    Tung, Yi-Ching
    Hsiao, Pei-Hung
    Lee, Jing-Sheng
    Tsai, Wen-Yu
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (02) : 148 - 155
  • [30] MCLENA-I: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease
    Decourt, Boris
    Wilson, Jeffrey
    Ritter, Aaron
    Dardis, Christopher
    DiFilippo, Frank P.
    Zhuang, Xiaowei
    Cordes, Dietmar
    Lee, Garam
    Fulkerson, Nadia D.
    St Rose, Tessa
    Hartley, Katurah
    Sabbagh, Marwan N.
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2020, 12 : 1 - 12